Formulation, Optimization and Evaluation of Delayed Release Tablet of Esomperazole Magnesium

References

[1] Vyas SP, Khar RK. Controlled drug delivery: Concepts and advances. 1st ed. New Delhi: Vallabh Prakashan; 2002.

[2] Chien YW. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 1982.

[3] Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. 10th ed. New Delhi: Vallabh Prakashan; 2007. p. 399.

[4] Li X, Jasti BR. Design of controlled release drug delivery systems. 1st ed. McGraw-Hill Professional; 2005.

[5] Jantzen GM, Robinson JR. Sustained and controlled-release drug delivery systems. Modern Pharmaceutics. 1995;121(4):501–502.

[6] Altaf AS, Friend DR. MASRx and COSRx sustained-release technology. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery technology. New York: Marcel Dekker; 2003. p. 996.

[7] Gwen MJ, Joseph RR. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. New York: Marcel Dekker; 1996;72(3):575.

[8] Borgquist P, Körner A, Larsson A. A model for the drug release from a polymer matrix tablet – effects of swelling and dissolution. J Control Release. 2006;113:216–225.

[9] Zalte HD, Saudagar RB. Review on sustained release matrix tablet. Int J Pharm Biol Sci. 2013;3(4):17–29.

[10] Remington: The science and practice of pharmacy. 21st ed. Vol 1. Wolters Kluwer Health (India); 2006. p. 939–964.

[11] Chugh I, Seth N, Rana AC, Gupta S. Oral sustain release drug delivery system: An overview. Int Res J Pharm. 2012;3(5):57–62.

[12] Bhargava A, Rathore RPS, Tanwar YS, Gupta S, Bhaduka G. Oral sustained release dosage form: An opportunity to prolong the release of drug. Int J Adv Res Pharm Bio Sci. 2013;3(1):7–14.

[13] Modi SA, Gaikwad PD, Banker VH, Pawar SP. Sustained release drug delivery system. Int J Pharma Res Dev. 2011;2(12):147–160.

[14] Gupta MM, Ray B. A review on: Sustained release technology. Int J Ther Appl. 2012;(8):1–23.

[15] Al-Zidan RN, Majeed SM, Al-Shaheen MK. Fabrication and evaluation of oral multi-particulate tablets of proton pump inhibitors: Esomeprazole as a model. Sys Rev Pharm. 2020;11(11):487–492.

[16] Yadav K, Singhai AK, Nayak A. Formulation of esomeprazole sustained release tablets using natural polymers. Int J Pharm Pharm Res. 2020;19(3):545–565.

[17] Sumeet Reddy D, Gudas GK. Formulation and evaluation of floating tablets of esomeprazole. Int J Pharm Anal Res. 2017;6(4):754–761.

[18] Naveen Kumar Y, Sreekanth J, Reddy PVC. Formulation development and in vitro evaluation of esomeprazole controlled release tablets by using various grades of Eudragit polymers. Indo Am J Pharm Res. 2017;7(1):7431–7439.

[19] Naveen Kumar Y, Sreekanth Y. Formulation development of controlled release formulation of esomeprazole sodium tablets. Indo Am J Pharm Sci. 2015;2(5):955–960.

[20] RK, Rao PM, Sivasankar R, Valli B. Formulation and evaluation of esomeprazole magnesium dihydrate multiple unit particulate system (pellets) as a delayed release dosage form. Int J Res Dev Pharm Life Sci. 2014;3(2):935–942.

[21] Malik D, Singh I. Formulation and evaluation of press coated tablets of esomeprazole for colonic delivery. Asian J Pharm. 2012;6:252–258.

[22] Suja C, Sismy C. Formulation and evaluation of sustained release dosage forms of norfloxacin. Int J Pharm Sci Nanotech. 2018;11(6). https://doi.org/10.37285/ijpsn.2018.11.6.6

[23] Ahmed M, Ahamed SK, Dewan SMR, Moghal MR. Development of sustained release matrix tablets of ramipril and evaluation of polymer effect on in-vitro release pattern. Int J Pharm Sci Res. 2013;4(3):1039–1045.

[24] Ahsan M, Abbas N, Hussain A, Saeed H, Shah PA, Mohammad S, et al. Formulation optimization and in-vitro evaluation of oral floating captopril matrix tablets using factorial design. Trop J Pharm Res. 2015;14(10):1737–1748.

[25] Ovenseri AC, Michael UU. Formulation and evaluation of effervescent floating matrix tablets of a biguanide using Grewia mollis gum. Asian J Appl Sci. 2019;12(2):91–98.

[26] Kumar A, Singh S, Sharma G, Sharma S, Verma A, Kaur R, et al. Formulation, optimization and evaluation of gastro-retentive floating microspheres of norfloxacin. Asian J Med Pharm Sci. 2013;3(23):12–17.

[27] Ramesh Y, Balachandra P, Chinnaiah S. Formulation and evaluation of floating microspheres of norfloxacin. Res J Chem Environ Sci. 2013;1(4):18–28.

[28] Venkateswarlu K, Preethi JK, Sai Kiran BS. Formulation development and in-vitro evaluation of floating tablets of ciprofloxacin HCl. Asian J Pharm. 2016;10(4):271–278.

[29] Saha RN, Sajeev C, Sahoo J. A comparative study of controlled release matrix tablets of diclofenac sodium, ciprofloxacin hydrochloride, and theophylline. Drug Deliv. 2001;8:149–154.

[30] Pasa G, Choudhury PK, Panigrahi G. Formulation design and optimization of oral floating matrix tablets of ciprofloxacin HCl by using HPMC and xanthan gum with experimental design. Asian J Pharm Res Dev. 2018;6(6):23–35.

[31] Malipeddi VR, Awasthi R, Dua K. Formulation and evaluation of controlled-release matrix systems of ciprofloxacin. Polym Med. 2017;47(2):101–106.

[32] Varshosaz J, Tavakoli N, Roozbahani F. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 2006;13:277–285.

@article{1724011,
      author = {Charu Jain, Dr. Pradeep Chauhan, Dr. Sandeep Jain, Dr. Bharat K. Tyagi},
      title = {Formulation, Optimization and Evaluation of Delayed Release Tablet of Esomperazole Magnesium},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {3659-3671},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724011.pdf},
      abstract = {The objective of the current investigation was to formulate delayed release tablets of Esomeprazole that could control the release of the drug thereby reducing its dosing frequency and improving the bioavailability. The objective was accomplished by preparation of the matrix tablets using HPMC K4M, carbopol 940 and Eudragit RLPO as the matrix forming polymers. The angle of repose for all formulations was found to be within the range from 23°13 to 28°15. This indicates that good flow property of powder blend. The bulk density and tapped density values were found to be within the range from 0.54 to 0.60 and 0.63 to 0.71 respectively. The Hausner’s ratio values were found to be within the range from 6.35 to 21.13. The friability of all formulation was in the range of 0.37% to 0.52% and the weight variation was in the range of 1.7 to 2.8 %. Swelling study was performed on all the formulation for 9 h and was found to be in the range of 1.32 to 5.22. The highest degree of swelling was achieved by F8 that contained equal concentration of HPMC K4M, carbopol 940 and Eudragit RLPO. The formulations F1, F2, F3 and F4 could not control the release for even up to 8 h. On the other hand, the formulation F5 was able to release almost 100% of the drug at the end of 10th whereas formulations F6 and F7 released 100% drug at the end of 11th hour.},
      keywords = {formulation; optimization; delayed release tablet; esomeprazole magnesium},
      month = {October},
  }